Mitsubishi Tanabe Of Japan, Vertex Of U.S. Change Hepatitis C Pact
This article was originally published in PharmAsia News
Executive Summary
Japan's Mitsubishi Tanabe Pharma and U.S.-based Vertex Pharmaceuticals have revised their licensing agreement for the MP-424 (peginterferon) drug to treat hepatitis C. The drug is still in Phase III Japanese trials, but the companies decided a change was needed to help get the drug through those trials. Under the new arrangement, Mitsubishi Tanabe is to pay Vertex $105 million for a license to use the trial data to develop the drug for use in combination with interferon to treat hepatitis C. The new agreement eliminates royalties linked to sales. (Click here for more - a subscription may be required